Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
17 May 2023

ORYZON to present trial in progress Phase Ib FRIDA study at the upcoming 2023 ASCO annual meeting

10 May 2023

ORYZON reports financial results and corporate update for quarter ended March 31, 2023

22 June 2023

MidCap Paris 2023

Paris

France

7-9 June 2023

Jefferies Healthcare Conference 2023

New York

NY

United States

5-8 June 2023

BIO International Conference 2023

Boston Convention & Exhibition Center in Boston

MA

United States

31 May - 1 June 2023

VI Ibero-American Congress CEAPI 2023

Madrid

Spain

30 May - 1 June 2023

Foro Medcap BME 2023

Palacio de la Bolsa

Madrid

Spain

14-23 May 2023

BioEquity Europe 2023

Spencer Dock, Dublin

Dublin

Ireland

9 May 2023

ORYZON to give updates on corporate progress in May-June

3 April 2023

ORYZON announces positive results from planned interim analysis of PORTICO, a Phase 2b adaptive trial in Borderline Personality Disorder

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Current page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel